BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1136 related articles for article (PubMed ID: 22985747)

  • 1. The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages.
    Huh JE; Jung IT; Choi J; Baek YH; Lee JD; Park DS; Choi DY
    Eur J Pharmacol; 2013 Jan; 698(1-3):57-66. PubMed ID: 22985747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formononetin attenuates osteoclastogenesis via suppressing the RANKL-induced activation of NF-κB, c-Fos, and nuclear factor of activated T-cells cytoplasmic 1 signaling pathway.
    Huh JE; Lee WI; Kang JW; Nam D; Choi DY; Park DS; Lee SH; Lee JD
    J Nat Prod; 2014 Nov; 77(11):2423-31. PubMed ID: 25397676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
    Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
    Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
    Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
    J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel isoflavone derivatives inhibit RANKL-induced osteoclast formation.
    Tang CH; Chang CS; Tan TW; Liu SC; Liu JF
    Eur J Pharmacol; 2010 Dec; 648(1-3):59-66. PubMed ID: 20850430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
    Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
    Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
    Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis.
    Konda VR; Desai A; Darland G; Bland JS; Tripp ML
    Arthritis Rheum; 2010 Jun; 62(6):1683-92. PubMed ID: 20201075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.
    Ikeda F; Matsubara T; Tsurukai T; Hata K; Nishimura R; Yoneda T
    J Bone Miner Res; 2008 Jun; 23(6):907-14. PubMed ID: 18251700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of inflammatory bone erosion by constitutively active STAT-6 through blockade of JNK and NF-kappaB activation.
    Hirayama T; Dai S; Abbas S; Yamanaka Y; Abu-Amer Y
    Arthritis Rheum; 2005 Sep; 52(9):2719-29. PubMed ID: 16142755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
    He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
    Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of Stewartia koreana on osteoclast differentiation and bone resorption.
    Park CK; Kim HJ; Kwak HB; Lee TH; Bang MH; Kim CM; Lee Y; Chung DK; Baek NI; Kim J; Lee ZH; Kim HH
    Int Immunopharmacol; 2007 Dec; 7(12):1507-16. PubMed ID: 17920527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
    Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NF-kappaB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor.
    Kubota T; Hoshino M; Aoki K; Ohya K; Komano Y; Nanki T; Miyasaka N; Umezawa K
    Arthritis Res Ther; 2007; 9(5):R97. PubMed ID: 17892600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.
    Kim WS; Kim HJ; Lee ZH; Lee Y; Kim HH
    Exp Cell Res; 2013 Feb; 319(4):436-46. PubMed ID: 23246654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.